Global Women's Health Therapeutics Market 2021
Description
Women’s health refers to the branch of medicine that focuses on the treatment and diagnosis of diseases and conditions that affect a woman’s physical and emotional well-being. The global women’s health therapeutics market is set to increase by US$ 15.08 billion from 2021 to 2027, representing a compound annual growth rate (CAGR) of 5.1% during the forecast period.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for women’s health therapeutics. The global women’s health therapeutics market is segmented on the basis of disease, and region. On the basis of disease, the global women’s health therapeutics market has been segmented into breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and polycystic ovary syndrome (PCOS). The breast cancer segment held the largest revenue share in 2020. In terms of geography, the global women’s health therapeutics market has been segmented into Asia Pacific, Europe, North America, and Rest of the World (RoW).
The global women’s health therapeutics market is highly competitive. Top players covered in Global Women’s Health Therapeutics Market Study are AbbVie Inc., Amgen Inc., Asahi Kasei Corporation, AstraZeneca plc, Bayer AG, Bristol Myers Squibb (BMS), Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the women’s health therapeutics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Disease: breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and polycystic ovary syndrome (PCOS)
Region: Asia Pacific, Europe, North America, and Rest of the World (RoW)
Years considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
– Get a comprehensive picture of the global women’s health therapeutics market
– Pinpoint growth sectors and trends for investment
Table of Contents
1. Market definition
2. Research methodology
3. Market data and outlook
3.1 Market size estimates
3.2 Forecast
4. Women’s health therapeutics market by disease
4.1 Breast cancer
4.2 Postmenopausal osteoporosis
4.3 Menopause
4.4 Endometriosis
4.5 Polycystic ovary syndrome (PCOS)
5. Women’s health therapeutics market by region
5.1 Asia Pacific
5.2 Europe
5.3 North America
5.4 Rest of the World (RoW)
6. Company profiles
6.1 AbbVie Inc.
6.2 Amgen Inc.
6.3 Asahi Kasei Corporation
6.4 AstraZeneca plc
6.5 Bayer AG
6.6 Bristol Myers Squibb (BMS)
6.7 Eisai Co., Ltd.
6.8 Eli Lilly and Company
6.9 F. Hoffmann-La Roche AG
6.10 Merck & Co., Inc.
6.11 Novartis International AG
6.12 Pfizer Inc.
6.13 Sanofi S.A.
6.14 Takeda Pharmaceutical Company Limited
7. Appendix
7.1 About StrategyHelix
7.2 Disclaimer